“POBA Plus”

"POBA Plus": will the balloon regain its luster?

Endovascular therapy of arterial occlusive disease has made impressive progress since the first balloon angioplasty conceived by Dr Charles T. Dotter in 1964, followed by the first peripheral balloon angioplasty by Dr Andreas Gruntzig in 1974. Each advancement has frequently faced skepticism after the initial clinical experience. Thankfully, skepticism was met in kind with research seeking faci...

Regulation of the p-hydroxybenzoic acid hydroxylase gene (pobA) in plant-growth-promoting Pseudomonas putida WCS358.

The regulation of the p-hydroxybenzoate hydroxylase gene (pobA) of Pseudomonas putida WCS358 involved in the catabolism of p-hydroxybenzoic acid (PHB) to the central intermediate protocatechuate was studied. Protocatechuic acid (PCA) is then degraded via the beta-ketoadipate pathway to form tricarboxylic acid intermediates. In several Gram-negative bacteria pobA has been found genetically linke...

Experience plus explanation

The more clearly the clinician comprehends the processes of clinical perception and of linking the experience with explanation, the more thoughtfully clinical students can be guided to construct an accurate 'clinical memory' of cases, and to construct a sound 'working knowledge' structure from their personal 'examined experience'. The structuring of the steps of clinical learning is intended as...

Comparison of Spironolactone plus Cyproterone Acetate plus Cyproterone Compound with Spironolactone plus Cyproterone Compound in Hirsutism: A randomized clinical trial

Background: Monotherapy is not usually effective in the treatment of hirsutism. Objective: Comparison of 2 therapeutic regimens in the treatment of hirsutism. Patients and methods: In this open parallel controlled clinical trial, 101 Patients suffering from hirsutism were randomly divided into two equal groups. 50 patients were treated with spironolactone (50 mg/day) plus cyproterone comp...

AH Plus